Berberine: A Rising Star in the Management of Type 2 Diabetes-Novel Insights into Its Anti-Inflammatory, Metabolic, and Epigenetic Mechanisms.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical and clinical literature without systematic meta-analytic pooling
PubMed 41471379 · doi:10.3390/ph18121890
What was done
The authors conducted a literature review of PubMed and Web of Science records up to 2025 detailing the pharmacological activities and molecular mechanisms of berberine in type 2 diabetes mellitus (T2DM). The synthesis examined glucose metabolism, insulin sensitivity, epigenetic actions, signaling pathways (including AKT, AMPK, and GLUTs), diabetic complications, and combination therapy approaches.
What was found
The abstract reports no numerical data, effect sizes, or statistical metrics. It qualitatively summarizes that berberine acts via multi-target pathways to regulate gluconeogenesis, glycogen synthesis, and glucose transport, and exerts anti-inflammatory, antioxidant, and epigenetic effects alone and in combination with agents like metformin, ginsenoside Rb1, and probiotics.
Why it matters
This review compiles the broad cellular and biochemical mechanisms underlying berberine's metabolic actions, helping contextualize its proposed use in diabetes management and complication prevention.
Limits
No quantitative findings, sample sizes, or clinical outcomes are reported in the abstract. As a narrative review combining bench, animal, and clinical literature, it provides mechanistic rationale rather than direct empirical evidence or meta-analytic effect estimates.
Cited by
- context Berberine is derived from tree bark and functions as a glucose scavenger.